Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Jin Amon

Psychiatry Owensboro, KY Medical Doctor

NPI 1669739777 CMS profile 1386797

2211 Mayfair Dr, Suite 409, Owensboro, KY 42301

Open in the dashboard

General payments

$1,513

100 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Jin Amon of Owensboro, KY is reported in the CMS Open Payments database as having received $1,513 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $154 12
2019 General $1,359 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jin Amon
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Jin Amon were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Jin Amon Psychiatry median Middle half National median
2019 $1,359 $184 $59–$605 $163
2020 $154 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Sunovion Pharmaceuticals Inc. $468 34 payments
  2. Allergan Inc. $255 20 payments
  3. Otsuka America Pharmaceutical, Inc. $197 11 payments
  4. Janssen Pharmaceuticals, Inc $174 11 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $83 7 payments
  6. Alkermes, Inc. $79 4 payments
  7. Vanda Pharmaceuticals Inc. $64 3 payments
  8. Lundbeck LLC $53 3 payments
  9. Neurocrine Biosciences, Inc. $51 3 payments
  10. Ironshore Pharmaceuticals Inc. $46 1 payment
  11. Other $44 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $1,483 99 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2020
  1. LATUDA $468 34 payments
  2. VRAYLAR $255 20 payments
  3. INVEGA SUSTENNA $174 11 payments
  4. ABILIFY MAINTENA $120 5 payments
  5. INVEGA TRINZA $115 7 payments
  6. ARISTADA INITIO $79 4 payments
  7. ARISTADA Cns $79 4 payments
  8. ARISTADA Cns $79 4 payments
  9. ARISTADA Cns $79 4 payments
  10. ARISTADA Cns $79 4 payments
  11. Other $640 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

1,656

Median for Psychiatry: 574

Drug cost

$211,473

Median for Psychiatry: $27,624

Branded share of claims

16.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 24 $150,738
Trintellix Vortioxetine Hydrobromide Brand 30 $17,018
Lurasidone Hcl Generic 20 $6,658
Vyvanse Lisdexamfetamine Dimesylate Brand 15 $6,567
Quetiapine Fumarate Er Quetiapine Fumarate Brand 22 $2,763
Olanzapine Generic 33 $2,754
Olanzapine Odt Olanzapine Brand 12 $2,626
Aripiprazole Generic 38 $2,108
Fluphenazine Hcl Generic 22 $1,997
Buspirone Hcl Generic 112 $1,246

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$18,047

Medicare's payments for the services billed

Medicare patients

35

Average age 59

Services billed

316

21 women, 14 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 71%
High blood pressure 63%
Arthritis 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record